Immix Biopharma (NASDAQ:IMMX – Get Free Report) is anticipated to announce its earnings results on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter.
Immix Biopharma Stock Up 1.1 %
Immix Biopharma stock opened at $1.82 on Tuesday. The business’s 50-day moving average price is $1.86 and its 200 day moving average price is $1.86. The firm has a market cap of $50.06 million, a price-to-earnings ratio of -2.14 and a beta of 0.26. Immix Biopharma has a 52 week low of $1.26 and a 52 week high of $3.35.
Analysts Set New Price Targets
Separately, HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Immix Biopharma in a research note on Monday, February 10th.
Immix Biopharma Company Profile
Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.
See Also
- Five stocks we like better than Immix Biopharma
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Super Micro Stock: $7.2M Call Options Signal Big Upside Potential
- What is a buyback in stocks? A comprehensive guide for investors
- Top 3 Buy-and-Hold Stocks for 2025: Long-Term Winners to Watch
- How to Buy Cheap Stocks Step by Step
- D-Wave Stock: Is Quantum Blockchain the Next Big Catalyst?
Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
